HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway

Because of its amplification and/or overexpression in many human tumors, the HER-2/neu proto-oncogene represents an attractive target for T-cell-mediated vaccination strategies. However, overexpression of oncogenes is often associated with defective expression of components of the MHC class I antigen-processing machinery (APM), thereby resulting in an immune escape phenotype of oncogene-transformed cells. To determine whether HER-2/neu influences the MHC class I antigen-processing pathway, the expression pattern of different APM components was examined in murine in vitro models of constitutive and tetracycline-controlled HER-2/neu expression. In comparison with HER-2/neu− control cells, HER-2/neu+ fibroblasts exhibit reduced levels of MHC class I surface antigens that were associated with impaired expression and/or function of the peptide transporter associated with antigen processing, the proteasome subunits low molecular weight protein 2 and low molecular weight protein 10, the proteasome activators PA28α and PA28β, and tapasin. These APM abnormalities resulted in reduced sensitivity to lysis by CTLs. The HER-2/neu-mediated immune escape phenotype could be corrected by IFN-γ treatment. The clinical relevance of this finding was supported by an inverse correlation between HER-2/neu and the peptide transporter associated with antigen-processing protein expression as determined by immunhistochemical analysis of a series of HER-2/neu− and HER-2/neu+ breast cancer specimens. Thus, a functional link between deficient APM component expression and HER-2/neu overexpression is proposed that might influence the design of HER-2/neu-targeted T-cell-based immunotherapeutic strategies.

[1]  B. Seliger,et al.  Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. , 2002, Cancer research.

[2]  B. Vandenbunder,et al.  Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway , 2002, Oncogene.

[3]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[4]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[5]  J. Murray,et al.  Clinical trials of HER-2/neu-specific vaccines. , 2000, Seminars in oncology.

[6]  B. Seliger,et al.  Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. , 2000, Tissue antigens.

[7]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[8]  C. Huber,et al.  Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. , 1999, Cancer research.

[9]  P. Musiani,et al.  Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.

[10]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[12]  Robert Tampé,et al.  Down‐regulation of the MHC class I antigen‐processing machinery after oncogenic transformation of murine fibroblasts , 1998, European journal of immunology.

[13]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[14]  T. Hunter.  Oncoprotein Networks , 1997, Cell.

[15]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[16]  H. von Melchner,et al.  Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. , 1996, Oncogene.

[17]  B. Seliger,et al.  Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. , 1996, Experimental hematology.

[18]  B. Seliger,et al.  Multiple Levels of MHC Class I Down‐Regulation by ras Oncogenes , 1996, Scandinavian journal of immunology.

[19]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[20]  R. Tampé,et al.  Functional expression and purification of the ABC transporter complex associated with antigen processing (TAP) in insect cells , 1994, FEBS letters.

[21]  R. Tampé,et al.  A sequential model for peptide binding and transport by the transporters associated with antigen processing. , 1994, Immunity.

[22]  H. Rammensee,et al.  Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA‐A2.1 , 1994, International journal of cancer.

[23]  B. Seliger,et al.  Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.

[24]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Neefjes,et al.  Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. , 1993, Science.

[26]  N. Lemoine,et al.  Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.

[27]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Pound,et al.  Modulation of MHC antigen expression by viruses and oncogenes , 1991, Immunology Today.

[29]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[30]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[31]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[32]  R. Linsk,et al.  Histocompatibility antigens on murine tumors. , 1985, Science.

[33]  J. Murray,et al.  Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity , 2004, Molecular and Cellular Biochemistry.

[34]  P. V. van Diest,et al.  T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[35]  Clement BordierO.  Phase Separation of Integral Membrane Proteins in Triton X-114 Solution , 2001 .

[36]  R. Tampé,et al.  Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. , 2001, Tissue antigens.

[37]  R. Coffey,et al.  Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Cheever,et al.  HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.

[39]  D. Lowy,et al.  Function and regulation of ras. , 1993, Annual review of biochemistry.